Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Saved in:
| Title: | Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. |
|---|---|
| Authors: | Zimmer JA; Eli Lilly and Company, Indianapolis, IN, USA., Sims JR; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: sims_john_r@lilly.com., Evans CD; Eli Lilly and Company, Indianapolis, IN, USA., Nery ESM; Eli Lilly and Company, Indianapolis, IN, USA., Wang H; Eli Lilly and Company, Indianapolis, IN, USA., Wessels AM; Eli Lilly and Company, Indianapolis, IN, USA., Tronchin G; Eli Lilly and Company, Indianapolis, IN, USA., Sato S; Eli Lilly and Company, Indianapolis, IN, USA., Raket LL; Eli Lilly and Company, Indianapolis, IN, USA., Andersen SW; Eli Lilly and Company, Indianapolis, IN, USA., Sapin C; Eli Lilly and Company, Indianapolis, IN, USA., Paget MA; Eli Lilly and Company, Indianapolis, IN, USA., Gueorguieva I; Eli Lilly and Company, Indianapolis, IN, USA., Ardayfio P; Eli Lilly and Company, Indianapolis, IN, USA., Khanna R; Eli Lilly and Company, Indianapolis, IN, USA., Brooks DA; Eli Lilly and Company, Indianapolis, IN, USA., Matthews BR; Eli Lilly and Company, Indianapolis, IN, USA., Mintun MA; Eli Lilly and Company, Indianapolis, IN, USA. |
| Corporate Authors: | Alzheimer’s Disease Neuroimaging Initiative; Eli Lilly and Company, Indianapolis, IN, USA. |
| Source: | The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2026 Feb; Vol. 13 (2), pp. 100446. Date of Electronic Publication: 2025 Dec 01. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
